- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
'Biogen has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow.'
All eyes are on Pfizer in the months ahead.
Pfizer post earnings beat.
The Justice Department is investigating the company's charitable contributions for kickbacks and false claims.
Wall Street at records.